MMIRF (MedMira) Return-on-Tangible-Equity: 0.00% (As of Jan. 2026)


What is MedMira Return-on-Tangible-Equity?

MedMira MMIRF +302.48% Return-on-Tangible-Equity is 0.00% as of Jan. 2026. The stock has 6 warning signs investors should review. Among 1,200 Biotechnology companies, MedMira ranks worse than 83333.25% on this metric.

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. MedMira's annualized net income for the quarter that ended in Jan. 2026 was $-1.91 Mil. MedMira's average shareholder tangible equity for the quarter that ended in Jan. 2026 was $-17.08 Mil. Therefore, MedMira's annualized Return-on-Tangible-Equity for the quarter that ended in Jan. 2026 was N/A%.

The historical rank and industry rank for MedMira's Return-on-Tangible-Equity or its related term are showing as below:

MMIRF's Return-on-Tangible-Equity is not ranked *
in the Biotechnology industry.
Industry Median: -42.435
* Ranked among companies with meaningful Return-on-Tangible-Equity only.

MedMira  (OTCPK:MMIRF) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


MedMira Return-on-Tangible-Equity Related Terms


MedMira Return-on-Tangible-Equity Historical Data

* Premium members only.

The historical data trend for MedMira's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MedMira Return-on-Tangible-Equity Chart

MedMira Annual Data
Trend Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MedMira Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MMIRF vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison

For the Biotechnology subindustry, MedMira's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MedMira Return-on-Tangible-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MedMira's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where MedMira's Return-on-Tangible-Equity falls into.



MedMira Return-on-Tangible-Equity Calculation

MedMira's annualized Return-on-Tangible-Equity for the fiscal year that ended in Jul. 2025 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Jul. 2025 )  (A: Jul. 2024 )(A: Jul. 2025 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Jul. 2025 )  (A: Jul. 2024 )(A: Jul. 2025 )
=-3.304/( (-13.152+-16.479 )/ 2 )
=-3.304/-14.8155
=N/A %

MedMira's annualized Return-on-Tangible-Equity for the quarter that ended in Jan. 2026 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Jan. 2026 )  (Q: Oct. 2025 )(Q: Jan. 2026 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Jan. 2026 )  (Q: Oct. 2025 )(Q: Jan. 2026 )
=-1.912/( (-16.71+-17.451)/ 2 )
=-1.912/-17.0805
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Jan. 2026) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.

What does a Return-on-Tangible-Equity of 0.00% mean?
MedMira (MMIRF) has a Return-on-Tangible-Equity of 0.00% as of Jan. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on MedMira and its competitors. According to the industry distribution chart, MedMira ranks #999999 out of 1200 companies in the Biotechnology industry.
Is MedMira's Return-on-Tangible-Equity too high?
MedMira's current Return-on-Tangible-Equity is 0.00%. Based on the distribution chart, MedMira ranks #999999 out of 1200 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does MedMira's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, MedMira ranks #999999 out of 1200 companies for Return-on-Tangible-Equity. This places MedMira in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on MedMira and its competitors. MedMira's current Return-on-Tangible-Equity is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedMira stock overvalued right now?
MedMira (MMIRF) has a current Return-on-Tangible-Equity of 0.00%. The current Return-on-Tangible-Equity is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For MedMira (MMIRF), the current Return-on-Tangible-Equity is 0.00% as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MedMira Business Description

Other Exchanges MIR:Canada
Address 155 Chain Lake Drive, Suite 1, Halifax, NS, CAN, B3S 1B3
MedMira Inc is a biotechnology company engaged in the research, development, and manufacturing of rapid diagnostics and technologies. The company operates in one reportable operating segment, rapid diagnostic products and services. Its product line includes HIV, COVID-19, syphilis, Multiplex, Miriad RVF Toolkit, and H. pylori. The company generates revenue from North America, Europe, and other regions, with the majority generated from North America.